Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
Developed in consultation with clinicians and patients for an enhanced user experience
India has taken the lead in recognising NAFLD as a major non-communicable disease
Apulki Healthcare is India's first PPP dedicated for cancer and cardiac care hospita
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
Quinidine Sulphate helps manage rare irregular heartbeat conditions
Focus on consolidation could help them strengthen their position in the competitive pharmaceutical industry, potentially driving expansion and improving efficiencies
These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity
The raised capital enables Medix Biochemica to continue execution of inorganic growth initiatives
Subscribe To Our Newsletter & Stay Updated
